US 9238042
Antisense modulation of interleukins 17 and 23 signaling
granted A61KA61K31/713A61K47/645
Quick answer
US patent 9238042 (Antisense modulation of interleukins 17 and 23 signaling) held by Sarepta Therapeutics, Inc. expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sarepta Therapeutics, Inc.
- Grant date
- Tue Jan 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K31/713, A61K47/645, A61P, A61P11/00